Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) has made history as the first CAR-T therapy approved for two types of leukemia: relapsed or refractory large B-cell lymphoma (LBCL) and relapsed or refractory mantle cell lymphoma (MCL).
CAR-T (chimeric antigen receptor T-cell) therapy is a revolutionary type of immunotherapy that reprograms a patient’s immune cells to target and attack cancer cells. Breyanzi targets CD19, a protein located on the surface of some malignant B cells. Breyanzi’s clearance for LBCL and MCL marks an essential advance in the treatment landscape for these severe forms of leukemia. LBCL and MCL are notoriously challenging to treat, especially when they reoccur or do not respond to standard therapy.
Breyanzi was approved by regulatory organizations such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) after clinical trials indicated its efficacy in producing lasting responses in individuals with relapsed or refractory LBCL and MCL.
Breyanzi’s clearance marks a significant milestone in the field of CAR-T therapy. It provides new hope to patients with certain forms of leukemia who have exhausted all other therapeutic choices. It demonstrates Bristol Myers Squibb’s dedication to developing novel medicines and improving outcomes for patients with hematologic malignancies.
